Aligos Therapeutics, Inc. (ALGS)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

5.34 on 9 Oct 2026

0 buys0 sales at will0 planned sales

Key numbers

Fiscal year 2025, ended 31 Dec 2025, as filed

Revenue

$2.19M

Net income

$24.19M

Free cash flow

$82.50M

Operating margin

-4,024.9%

Net margin

-1,106.7%

Return on equity

-45.2%

Return on capital

-129.8%

Revenue growth, 1 yr

-39.5%

Revenue and profit

Fiscal years, as filed with the SEC · point at a year for the detail

Full statements →

RevenueNet incomeLoss

Latest insider transactions

From Form 4, most recent first

All of them →

Date	Insider	Type	Value	Of own stake
25 Oct 2023	Nuechterlein Carole Director	Bought	$6.00M	257%
20 Oct 2020	Vivo Capital VIII, LLC 10% owner	Bought	$7.25M	18.4%
20 Oct 2020	Novo Holdings A/S 10% owner	Bought	$3.00M	8.3%
20 Oct 2020	Woiwode Thomas Director	Bought	$3.00M	30.2%
20 Oct 2020	Versant Venture Capital VI, L.P. 10% owner	Bought	$3.00M	30.2%
20 Oct 2020	Vivo Capital VIII, LLC 10% owner	Bought	$1.00M	18.4%

Clue Score

How it works

31out of 100

Profitability 20

Financial strength 59

Growth 0

Insiders 50

Strongest on financial strength (59), weakest on growth (0). A score of the business, not of the price.

What insiders did

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan

Every insider, every trade →

Profile

Sector: Health care
Industry: Biological Products, (No Diagnostic Substances)
Country: United States
SEC filings: EDGAR →